» Articles » PMID: 27406414

Antioxidant Activity of 3-methyl-1-phenyl-2-pyrazolin-5-one

Overview
Journal Redox Rep
Date 2016 Jul 14
PMID 27406414
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The antioxidant activity of an anti-ischemic agent, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), was examined. The pKa value of MCI-186 is 7.0 and the rate of oxidation of MCI-186 initiated with an azo compound increased with increasing pH, suggesting that the anionic form of MCI-186 is much more reactive than the non-ionic form. The major products were 3-methyl-1-phenyl-2-pyrazolin-4,5-dione (4,5-dione) and 2-oxo-3-(phenylhydrazono)-butanoic acid (OPB). Hydrolysis of 4,5-dione gave OPB. The minor intermediate product was 4-hydroxy-4-(3-methyl-1-phenyl-1H-pyrazolin-5-on-4-yl)-3-methyl-1-phenyl-1H-pyrazolin-5-one (BPOH). The nucleophilic attack of the anionic form of MCI-186 to 4,5-dione is likely to give BPOH. MCI-186 (50 μM) inhibited the aerobic oxidation at 37°C of 5.2 mM unilamellar soybean phosphatidylcholine (PC) liposomal membranes, initiated with a water-soluble initiator, as efficientlyas did ascorbate (100 μM). MCI-186 (50 μM) also inhibited the oxidation of the same PC liposomal membranes, this time initiated with a lipid-soluble initiator, almost as efficiently as did α-tocopherol (2 μM). Furthermore, the combination of MCI-186 with ascorbate or α-tocopherol showed almost complete inhibition of PC oxidation induced by both initiators. These data suggest that MCI-186 may work as a good antioxidant in cellular systems as well as in cell-free systems.

Citing Articles

Discovery of selective ROCK2 inhibitors with free radical scavenging ability for the treatment of gouty arthritis.

Cao R, Song C, Wang Z, Lv B, Xiao W, Chen G Mol Divers. 2025; .

PMID: 39847187 DOI: 10.1007/s11030-024-11054-w.


Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review.

Ansari U, Alam M, Nadora D, Muttalib Z, Chen V, Taguinod I AIMS Neurosci. 2024; 11(2):166-177.

PMID: 38988889 PMC: 11230861. DOI: 10.3934/Neuroscience.2024010.


Current perspectives on neuromodulation in ALS patients: A systematic review and meta-analysis.

Jimenez-Garcia A, Bonnel G, Alvarez-Mota A, Arias N PLoS One. 2024; 19(3):e0300671.

PMID: 38551974 PMC: 10980254. DOI: 10.1371/journal.pone.0300671.


Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases.

Yamashita T, Abe K Int J Mol Sci. 2024; 25(5).

PMID: 38474192 PMC: 10932469. DOI: 10.3390/ijms25052945.


Edaravone: A Novel Possible Drug for Cancer Treatment?.

Duranti E, Cordani N, Villa C Int J Mol Sci. 2024; 25(3).

PMID: 38338912 PMC: 10855093. DOI: 10.3390/ijms25031633.